News
03-04-2011, 12:16 AM
BioSante Pharmaceuticals, Inc. today announced publication of results from a Phase II clinical study that show BioSante's Pancreas Cancer Vaccine increased the median survival of resected pancreatic cancer patients from 15 to 20 months, as reported in published data, to 24.8 months, an increase of more than 25 percent.
More... (http://www.news-medical.net/news/20110304/BioSantes-Pancreas-Cancer-Vaccine-increases-median-survival-of-resected-pancreatic-cancer-patients.aspx)
More... (http://www.news-medical.net/news/20110304/BioSantes-Pancreas-Cancer-Vaccine-increases-median-survival-of-resected-pancreatic-cancer-patients.aspx)